
HIV infection continues to be among the leading causes of morbidity and mortality, especially in Africa. The prevalence of herpes simplex virus type 2 (HSV-2) has already reached high seroprevalence of up to 90% in HIV-seropositive individuals, and HSV-2 is now the leading cause of genital ulcer disease in both developing and developed countries. The role of HSV-2 as a biological cofactor in HIV acquisition and transmission may have contributed substantially to HIV diffusion, also facilitating HIV spread among the low-risk population who have stable long-term sexual partnerships. To date, no vaccine to prevent HSV-2 acquisition or reactivation has been developed, although antivirals have been shown to be safe and effective in reducing HSV-2 shedding frequency and the duration of genital ulcer disease. The paper under evaluation confirms the favorable effect of therapies aimed at suppressing HSV-2 reactivation in HIV-seropositive patients on HIV plasma and vaginal load. In this study, aciclovir 400 mg twice daily was able to significantly reduce plasma and genital HIV RNA, the frequency of HSV shedding, genital HSV-2 DNA and the frequency of genital ulcerations. These results suggest that HSV-2 control with low-cost aciclovir can play an important role in reducing HIV spread, mainly in developing countries, where costs limit the use of highly active antiretroviral therapy.

**Keywords:** aciclovir • HIV • HIV transmission • HSV


HIV infection continues to be among the leading causes of morbidity and mortality, especially in Africa. The prevalence of herpes simplex virus type 2 (HSV-2) has already reached high seroprevalence of up to 90% in HIV-seropositive individuals, and HSV-2 is now the leading cause of genital ulcer disease in both developing and developed countries. The role of HSV-2 as a biological cofactor in HIV acquisition and transmission may have contributed substantially to HIV diffusion, also facilitating HIV spread among the low-risk population who have stable long-term sexual partnerships. To date, no vaccine to prevent HSV-2 acquisition or reactivation has been developed, although antivirals have been shown to be safe and effective in reducing HSV-2 shedding frequency and the duration of genital ulcer disease. The paper under evaluation confirms the favorable effect of therapies aimed at suppressing HSV-2 reactivation in HIV-seropositive patients on HIV plasma and vaginal load. In this study, aciclovir 400 mg twice daily was able to significantly reduce plasma and genital HIV RNA, the frequency of HSV shedding, genital HSV-2 DNA and the frequency of genital ulcerations. These results suggest that HSV-2 control with low-cost aciclovir can play an important role in reducing HIV spread, mainly in developing countries, where costs limit the use of highly active antiretroviral therapy.

**Keywords:** aciclovir • HIV • HIV transmission • HSV


HIV infection continues to be among the leading causes of morbidity and mortality, especially in Africa. The prevalence of herpes simplex virus type 2 (HSV-2) has already reached high seroprevalence of up to 90% in HIV-seropositive individuals, and HSV-2 is now the leading cause of genital ulcer disease in both developing and developed countries. The role of HSV-2 as a biological cofactor in HIV acquisition and transmission may have contributed substantially to HIV diffusion, also facilitating HIV spread among the low-risk population who have stable long-term sexual partnerships. To date, no vaccine to prevent HSV-2 acquisition or reactivation has been developed, although antivirals have been shown to be safe and effective in reducing HSV-2 shedding frequency and the duration of genital ulcer disease. The paper under evaluation confirms the favorable effect of therapies aimed at suppressing HSV-2 reactivation in HIV-seropositive patients on HIV plasma and vaginal load. In this study, aciclovir 400 mg twice daily was able to significantly reduce plasma and genital HIV RNA, the frequency of HSV shedding, genital HSV-2 DNA and the frequency of genital ulcerations. These results suggest that HSV-2 control with low-cost aciclovir can play an important role in reducing HIV spread, mainly in developing countries, where costs limit the use of highly active antiretroviral therapy.

**Keywords:** aciclovir • HIV • HIV transmission • HSV
relative risk of two- to five-fold of transmitting HIV from individuals coinfected with HSV-2 compared with individuals who are HSV-2 seronegative [32,33]. In addition, HIV infection has been shown to substantially increase mucosal HSV-2 shedding [34–40]. These observations led to several proof-of-concept, placebo-controlled trials to assess the effect of HSV-2 suppression on HIV infectiousness.

**Methods**

The authors recruited 300 women out of the 583 screened from the community or from support groups for people living with HIV/AIDS in Johannesburg, South Africa. The eligibility criteria were: age 18 years or older; HIV and HSV-2 seropositivity; clinically asymptomatic for HIV, according to WHO criteria [41]; a CD4 cell count of at least 250 cells/ml; negative urine pregnancy test; not breastfeeding; and no contraindication to aciclovir suppressive therapy.

Participants were randomized 1:1 to aciclovir 400 mg twice daily or matching placebo. Following randomization, participants were seen at monthly clinic visits for a total of three visits (M1, M2 and M3). Information on symptoms, adverse events and adherence was obtained and blood and genital samples were collected. All participants received pretest and post-test STI/HIV counseling, regular risk-reduction counseling, free condoms, treatment of laboratory-diagnosed STIs and STI syndromes, and referral to local HIV treatment centers. GUD episodes were treated presumptively as genital herpes with aciclovir 400 mg three-times daily for 5 days, irrespective of study group. A standardized cervico–vaginal lavage (CVL) was performed at all visits for the measurements of genital HIV and HSV-2 shedding. The primary outcomes of the trial were the detection and quantity of genital HIV RNA in CVL at M3. Secondary outcomes included quantity of plasma HIV RNA (log_{10} copies/ml), CD4 cell count, detection and quantity of genital HSV-2 DNA in CVL, and occurrence of GUD episodes.

**Results**

Results from 269 (90%) participants (132 aciclovir and 137 placebo) out of 300 randomized individuals were available for the primary analysis of outcomes at the M3 visit and 288 (96%) participants (146 aciclovir and 142 placebo) for the summary and repeat measures analyses. Overall, 541 out of 604 (90%) and 545 out of 592 (92%) of the planned clinical visits were completed by participants in the aciclovir and placebo groups, respectively. There was no association between treatment arm and missed visits. The treatment groups were well balanced for most baseline characteristics. Across the two enrolment visits, there were similar proportions of persistent HIV shedders in the aciclovir and placebo groups (42 vs 41%). The proportion of HIV/HSV-2 shedders was similar in the two groups (30 vs 28%). The proportion of women with detectable genital HIV RNA was consistently lower in the aciclovir group. Using summary measures analysis, there was evidence for a strong effect of aciclovir in reducing the frequency of HIV shedding among women (adjusted odds ratio [OR]: 0.57; 95% CI: 0.36–0.89; p = 0.013). Among women with detectable genital HIV, the mean quantity of HIV RNA was lower in the aciclovir group (-0.13 log_{10} copies/ml; 95% CI: -0.28–0.03), although the evidence for a difference was weak (p = 0.12). Significant reductions in M3 plasma HIV RNA (-0.34 log_{10} copies/ml; 95% CI: -0.54 to -0.15; p < 0.001), A similar result was observed when all four follow-up visits were included. There was a reduction of 0.27 log_{10} copies/ml (95% CI: 0.13–0.41; p < 0.001) across all visits, equivalent to a 46% reduction in mean HIV plasma viral load. Significant reductions in genital HSV-2 DNA (8 vs 20%; relative risk [RR]: 0.37; 95% CI: 0.19–0.73) and genital ulceration (8 vs 18%; RR: 0.43; 95% CI: 0.22–0.84) were also observed in the aciclovir group.

**Discussion**

Although the present report and other smaller trials conducted among women in Burkina Faso and Thailand, and one conducted among homosexual men in Peru, have shown reductions in plasma and genital or rectal HIV viral loads using aciclovir or valaciclovir [32,43], two recently published randomized controlled trials have shown that daily aciclovir does not reduce the risk of HIV acquisition in HSV-2 seropositive, HIV-seronegative individuals. The necessary reduction in the frequency of genital HIV RNA shedding in order to reduce sexual transmission of HIV is unclear. Clinical assessment of HSV-2 disease severity, as defined by the number of recurrences, appears to be a poor predictor of the risk of transmission to sexual partners [44]. Although individuals with frequent recurrences are most likely to benefit clinically from suppressive antiviral therapy, they do not appear to have any higher risk of transmission than those with less frequent recurrences. As aciclovir suppressive therapy was evaluated as a means of reducing HIV transmission, it is also likely that HIV transmission can be independent of the frequency of HSV-2 recurrences [44].

The present research was conducted as an intention-to-treat study without reporting clinical failures of the suppressive therapy or looking for aciclovir-resistant strains. To our knowledge, the prevalence of aciclovir-resistant strains in immunocompetent and HIV patients in Africa is not known and, unfortunately, it was not evaluated in these studies. It is likely to be quite high among HIV patients, reducing the effect of the suppressive therapy at population level. It is known that aciclovir-resistant HSV can emerge rapidly during the course of antiviral therapy in immunocompromised patients [45]. Moreover, a continuing survey of HSV isolates from HIV-positive patients in the USA and Canada from 1998 to 2000 indicates that the prevalence of resistant HSV is approximately 6% [46]. In addition, it is worth mentioning that in a recent study in immunocompetent women, aciclovir-sensitive and aciclovir-resistant isolates were detected in samples collected on the same day from separate anatomic sites in three women [47]. In that study, the recovery of aciclovir-resistant HSV-2 isolates was obtained during both symptomatic recurrences of genital herpes and episodes of subclinical shedding. Moreover, the lack of a complete correlation between in vitro susceptibility of viral isolates and clinical response implicates other factors in the clinical outcome. These include the antiviral medication (dose, dose frequency,
route of administration and level of compliance), absorption and metabolism of the antiviral, immunological response of the patient and heterogeneity of the virus population [48]. Hence, data on HIV viral load in the blood or at genital level during HSV-2 suppressive therapy with aciclovir could be underestimated by the presence of aciclovir-resistant strains or reduced intestinal absorption of aciclovir in this population.

An interesting point is that it is likely that now we have the answer to a long-standing controversy: in the early 1990s, some clinical studies indicated that aciclovir, combined with zidovudine, improves survival time for HIV-infected individuals, although exactly how aciclovir prolongs survival was not known [48,49]. A 26% decrease in the risk of death was obtained in persons taking both aciclovir and zidovudine. If aciclovir treatment was initiated after a clinical diagnosis of AIDS, the risk of death was reduced by 44% [49]. At that time, those risk reductions were roughly equivalent to an increased survival time of 6 months to 1 year. Some researchers hypothesized that herpes viruses were cofactors in the progression of HIV disease and that aciclovir was suppressing herpes infections. However, even if studies using both high-dose aciclovir and aciclovir at a dose sufficient to suppress HSV recurrences (i.e., 600–800 mg/day) as a cotherapy to zidovudine had no efficacy in women seropositive for HSV-1 and seronegative for both HSV-1 and HSV-2 at baseline. Unfortunately, it has been shown that aciclovir suppressing also reduces CMV disease, but a trend toward earlier mortality for aciclovir recipients was seen [50]. Now we can say that it is likely that the prolonged survival in patients on aciclovir was due to a reduced HIV load, attained due to HSV suppression. When highly active antiretroviral therapy was introduced, this modest, but important effect was obscured by the HIV suppression by antiretrovirals [51].

Expert commentary & five-year view

The role of HSV-2 as a biological cofactor in HIV acquisition and transmission may have contributed substantially to HIV, particularly by facilitating HIV spread. This finding suggests that control of HSV-2 infection may be an effective intervention in reducing HIV spread in Africa. Our current tools for reducing the impact of HSV-2, such as the use of HSV-specific antivirals such as aciclovir to suppress HSV-2 reactivation, may not be effective enough to reduce the effect of HSV-2 on increasing HIV susceptibility, which contributes to the HSV–HIV synergy. However, a HSV-2 vaccine may be an effective intervention for preventing the interaction of the two infections by removing HSV-2 as a risk factor for HIV acquisition and transmission.

A few years ago, studies suggested that the glycoprotein D vaccine has efficacy against genital herpes in women who are seronegative for both HSV-1 and HSV-2 at baseline. Unfortunately, it had no efficacy in women seropositive for HSV-1 and seronegative for HSV-2, or in men, regardless of their HSV serologic status [52]. At present, a number of herpes vaccines are under development and we hope to have an efficient vaccine available in the next few years.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Key issues

- The prominent effect of herpes simplex virus type 2 (HSV-2) in facilitating the spread of HIV epidemic in sub-Saharan Africa is related to:
  - The biology of HSV-2 as a chronic infection and a leading cause of clinical and subclinical genital ulcers
  - The high HSV-2 prevalence
  - Enhanced HIV acquisition in HSV-2-seropositive individuals
  - Enhanced HIV infectivity in dually infected subjects
- HSV-2 suppressive therapy with aciclovir reduces HIV-1 plasma viral load and alters the pattern of genital HIV-1 shedding.
- HSV-2 suppressive therapy with aciclovir or valaciclovir does not appear to reduce HIV acquisition in some studies in Africa. Adherence, absorption and HSV-2 resistance can account for these negative results.
- A HSV-2 vaccine could limit the genital herpes epidemic and reduce the spread of HIV infection.

References

3 Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl. 1), S3–S28 (2002).


Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2


**Key Paper Evaluation**

**Aciclovir, herpes viruses & HIV**

**Affiliations**

- Antonio Volpi
  Department of Public Health, University of Rome Tor Vergata, Via Montpellier 1, 00133 Roma, Italy
  Tel.: +39 062 090 3440
  Fax: +39 062 090 3441
  volpi@uniroma2.it

- Cesare Sarrecchia
  Department of Public Health, University of Rome Tor Vergata, Via Montpellier 1, 00133 Roma, Italy

- Pasquale Sordillo
  Department of Public Health, University of Rome Tor Vergata, Via Montpellier 1, 00133 Roma, Italy